Shanghai Henlius up for Hong Kong IPO

Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Dec. 14 to list on the Hong Kong stock exchange.

Shanghai Henlius' lead compound is HLX01, a biosimilar of cancer and autoimmune drug MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY). China's National Medical Products Administration (NMPA) is reviewing an NDA for the drug under Priority Review to treat non-Hodgkin lymphoma; Henlius expects a decision this year or early next...